09 September 2015 : Clinical Research
Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled TrialWenjun WuAB, Ying LiBC, Xiong ChenBC, Dini LinCD, Songying XiangCD, Feixia ShenABCDEFG, Xuemei GuDE
Med Sci Monit 2015; 21:2678-2684
BACKGROUND: This study aimed to evaluate the efficacy and safety of linagliptin (a novel dipeptidyl peptidase (DPP)-4 inhibitor) on glucose metabolism and β-cell function in Chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus (T2DM).
MATERIAL AND METHODS: Newly-diagnosed and drug-naïve T2DM patients were enrolled. After 4-week lifestyle modulation and 2-week placebo run-in, 57 patients were randomized to double-blind treatment with linagliptin (n=34) or placebo (n=23). The primary endpoint was the change from baseline in glycosylated hemoglobin A1c (HbA1c) after 24 weeks. Fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2h-PPG), fasting insulin, proinsulin-to-insulin ratio, homeostasis model assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β-cell function (HOMA-β) were also evaluated.
RESULTS: Baseline characteristics were similar between the 2 groups. Compared with placebo, linagliptin therapy resulted in a significant decrease in HbA1C (–1.2±0.7% vs. –0.4±0.4%, P<0.001), FBG (–0.98±1.17 vs. –0.32±0.51 mmol/L, P=0.011, and 2h-PPG (–2.02±0.94 vs. –0.97±0.63 mmol/L, P<0.001). Significant differences were observed for the proinsulin/insulin ratio (P<0.001) and HOMA-β index (P=0.001). Rates of adverse events were similar between the 2 groups (30.3% vs. 27.3%). All adverse events were mild. One patient discontinued participation due to pregnancy.
CONCLUSIONS: Linagliptin treatment resulted in a significant and clinically meaningful improvement of glycemic control in drug-naïve Chinese patients with T2DM, as well as improved parameters of b-cell function. Linagliptin had an excellent safety profile.
Keywords: Blood Glucose - analysis, Blood Pressure, Body Mass Index, Diabetes Mellitus, Type 2 - drug therapy, Dipeptidyl-Peptidase IV Inhibitors - therapeutic use, Double-Blind Method, Hemoglobin A, Glycosylated - metabolism, Homeostasis, Hyperglycemia - drug therapy, Hypoglycemic Agents - therapeutic use, Insulin Resistance, Insulin-Secreting Cells - metabolism, Life Style, Linagliptin - therapeutic use, Postprandial Period, Time Factors
01 December 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit 2021; 27:e935624
03 December 2021 : Laboratory ResearchInfluenza and Influenza-Like Respiratory Virus Infections in Children During the 2019/20 Influenza Season a...
Med Sci Monit In Press; DOI: 10.12659/MSM.934862
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems Duri...
Med Sci Monit 2022; 28:e935299
06 Dec 2021 : Animal ResearchAstragalus Flavone Induces Proliferation and Differentiation of Neural Stem Cells in a Cerebral Infarction ...
Med Sci Monit In Press; DOI: 10.12659/MSM.933830
06 Dec 2021 : Clinical ResearchAlteration of Serum Metabolites in Women of Reproductive Age with Chronic Constipation
Med Sci Monit In Press; DOI: 10.12659/MSM.934117
06 Dec 2021 : Clinical ResearchBody Composition Changes and Related Factors in Patients with Ulcerative Colitis: A Retrospective Single-Ce...
Med Sci Monit In Press; DOI: 10.12659/MSM.933942
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700